TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said that it has
reached a strategic collaboration with Mass General Brigham that is focused on
translational medicine and early development to establish an integrated approach
to scientific advancement and clinical expertise.

The company stated that the five-year collaboration will focus on oncology, rare
disease, and cell and gene therapies.

Astellas noted that the collaboration will leverage Mass General Brigham's
clinical and research expertise, and capabilities including clinical data and
human-derived cell models.

For More Such Health News, visit rttnews.com



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX